Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764. https://doi.org/10.1155/2020/3491764.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhatia HS, Wilkinson MJ. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022;11:6040. https://doi.org/10.3390/jcm11206040.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711. https://doi.org/10.1016/j.jacc.2016.11.042.

Article  CAS  PubMed  Google Scholar 

Mach F, Baigent C, Catapano A, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  PubMed  Google Scholar 

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer C. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374–92. https://doi.org/10.1016/j.jacl.2019.04.010.

Article  PubMed  Google Scholar 

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47. https://doi.org/10.1161/01.cir.97.18.1837.

Article  CAS  PubMed  Google Scholar 

Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105:310–5. https://doi.org/10.1161/hc0302.102575.

Article  PubMed  Google Scholar 

Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. https://doi.org/10.1016/s0195-668x(03)00114-3.

Article  CAS  PubMed  Google Scholar 

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136. https://doi.org/10.1136/bmj.39261.471806.55.

Article  PubMed  PubMed Central  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart association task force on clinical practice guidelines. Circulation. 2019;139:e1082–143. https://doi.org/10.1161/CIR.0000000000000625.

Article  PubMed  Google Scholar 

Kronenberg F, Mora S, Stroes ES, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–46. https://doi.org/10.1093/eurheartj/ehac361.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374:107–20. https://doi.org/10.1016/j.atherosclerosis.2023.04.012.

Article  CAS  PubMed  Google Scholar 

Lp(a) Clinical Guidance. https://www.lpaclinicalguidance.com. Accessed 17 Apr 2024.

Nordestgaard B, Chapman MJ, Ray K, Borén J, Andreotti F, Watts G, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–53. https://doi.org/10.1093/eurheartj/ehq386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–75. https://doi.org/10.1194/jlr.R071233.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X, Yusuf S. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472–82. https://doi.org/10.1161/CIRCULATIONAHA.118.034311.

Article  CAS  PubMed  Google Scholar 

Muzzio M, Motti JMB, Paz Sepulveda PB, Yee M-C, Cooke T, Santos MR, Ramallo V, Alfaro EL, Dipierri JE, Bailliet G, Bravi CM, Bustamante CD, Kenny EE. Population structure in Argentina. PLoS ONE. 2018;13:e0196325. https://doi.org/10.1371/journal.pone.0196325.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein (a) prospective 15-year outcomes in the Bruneck study. J Am Coll Cardiol. 2014;64:851–60. https://doi.org/10.1016/j.jacc.2014.03.061.

Article  PubMed  Google Scholar 

Ghavami M, Abdshah A, Esteghamati S, Hafezi-Nejad N, Nakhjavani M, Esteghamati A. Serum lipoprotein(a) and reclassification of coronary heart disease risk; application of prediction in a cross-sectional analysis of an ongoing Iranian cohort. BMC Public Health. 2023;23:2402. https://doi.org/10.1186/s12889-023-17332-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146–56. https://doi.org/10.1016/j.jacc.2012.12.023.

Article  CAS  PubMed  Google Scholar 

Tschiderer L, Seekircher L, Willeit P, Peters SAE. Assessment of cardiovascular risk in women: progress so far and progress to come. Int J Womens Health. 2023;15:191–212. https://doi.org/10.2147/IJWH.S364012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, Huck DM, Divakaran S, Hainer J, Kaur G, Blaha MJ, Cannon CP, Plutzky J, Januzzi JL, Booth JN 3rd, López JAG, Kent ST, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83:873–86. https://doi.org/10.1016/j.jacc.2023.12.031.

Article  CAS  PubMed  Google Scholar 

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275–84. https://doi.org/10.1093/eurheartj/ehz310.

Article  CAS  PubMed  Google Scholar 

Feng T, Li Y, Xue X, Yang W, Li Q, Huang Y, Zhu T, Wang J, Xu L, Li X, Gao J, Sun S, Zhu B, Zhang S, Cao B, Xuan J, Zhao Z, Qian B. Association of statin use and increase in lipoprotein(a): a real-world database research. Eur J Med Res. 2023;28:212. https://doi.org/10.1186/s40001-023-01155-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu Z, Hu L, Sun C, Wang Z, Zhang X, Wu M, Liu L. Effect of different types and dosages of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) levels: a network meta-analysis. J Cardiovasc Pharmacol. 2023;81:445–53. https://doi.org/10.1097/FJC.0000000000001419.

Article  CAS  PubMed  Google Scholar 

O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Pineda AL, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.

Article  CAS  PubMed  Google Scholar 

Fragasso G, Margonato A, Spoladore R, Lopaschuk GD. Metabolic effects of cardiovascular drugs. Trends Cardiovasc Med. 2019;29:176–87. https://doi.org/10.1016/j.tcm.2018.08.001.

Article  CAS  PubMed  Google Scholar 

Marques-Vidal P, Montaye M, Haas B, Bingham A, Evans A, Juhan-Vague I, Ferrières J, Luc G, Amouyel P, Arveiler D, McMaster D, Ruidavets JB, Bard JM, Scarabin PY, Ducimetière P. Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME study. J Hum Hypertens. 2000;14:511–8. https://doi.org/10.1038/sj.jhh.1001061.

Article  CAS  PubMed  Google Scholar 

Sukkari MH, Al-Bast B, Al Tamimi R, Giesing W, Siddique M. Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—a review of the evidence. Am J Prev Cardiol. 2023;15: 100579. https://doi.org/10.1016/j.ajpc.2023.100579.

Article  PubMed  PubMed Central  Google Scholar